Fujita Yuya, Nawata Masao, Nagayasu Atsushi, Someya Kazuki, Saito Kazuyoshi, Tanaka Yoshiya
The Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Case Rep Rheumatol. 2019 Jul 9;2019:5293981. doi: 10.1155/2019/5293981. eCollection 2019.
Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks. In addition, the skin sclerosis in systemic sclerosis showed an improvement. Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased. To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes. We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks.
巴瑞替尼是一种用于治疗类风湿性关节炎的 Janus 激酶 1/2（JAK1/2）抑制剂。一名 71 岁的女性患有类风湿性关节炎，并发系统性硬化症和 1 型糖尿病，对多种改善病情的抗风湿药物耐药，开始使用巴瑞替尼治疗。服用巴瑞替尼后，她的类风湿性关节炎疾病活动度从治疗早期就开始减轻，且效果维持了长达 52 周。此外，系统性硬化症的皮肤硬化情况有所改善。关于对 1 型糖尿病的影响，每日所需胰岛素剂量和糖化血红蛋白（HbA1c）水平均有所下降。迄今为止，尚无研究证明巴瑞替尼对系统性硬化症或 1 型糖尿病有效。我们报告巴瑞替尼对系统性硬化症、1 型糖尿病以及类风湿性关节炎均有效，且效果维持长达 52 周。
